Par Pharmaceutical (PRX) Tops Q2 EPS Vews; Revs Strong
Tweet Send to a FriendGet Alerts PRX Hot Sheet
Price: $49.98 --0%
EPS Growth %: +92.9%
Financial Fact:
Net income (loss): -0.79
Today's EPS Names:
LBIX, ESEA, ISS, More
EPS Growth %: +92.9%
Financial Fact:
Net income (loss): -0.79
Today's EPS Names:
LBIX, ESEA, ISS, More
Trade PRX Now!
Par Pharmaceutical (NYSE: PRX) reported Q2 EPS of $1.62, $0.50 better than the analyst estimate of $1.12. Revenue for the quarter came in at $294.3 million versus the consensus estimate of $291.3 million.
For earnings history and earnings-related data on Par Pharmaceutical (PRX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Par Pharmaceutical (PRX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- UPDATE: Aruba Networks, Inc. (ARUN) Misses Q3 EPS by 4c, Guidance Light
- Leading Brands Inc New (LBIX) Reports Breakeven Q4 Loss
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
